RSV Vaccine Offers Competition to GSK and Pfizer
- Moderna’s RSV vaccine receives US approval
- First mRNA vaccine for a disease other than COVID-19
- Approval for adults aged 60 and older
- Competition with GSK PLC and Pfizer Inc.’s vaccines
- RSV shot to be available in fall
- Single-dose, pre-filled syringes for convenience
Moderna Inc.’s respiratory syncytial virus (RSV) vaccine for older adults has received US regulatory approval, marking the first time an mRNA vaccine has been approved for a disease other than COVID-19. The Food and Drug Administration (FDA) approved Moderna’s mResvia for adults aged 60 and older, introducing competition for RSV vaccines recently launched by GSK PLC and Pfizer Inc. The FDA’s decision gives Moderna a second approved product as sales of its first product, the COVID-19 vaccine Spikevax, have been declining. The shot is expected to be available in time for the start of this fall’s RSV season. RSV often causes mild cold-like symptoms but can be severe, particularly for infants and older adults. About 60,000 to 160,000 people aged 65 and older are hospitalized each year due to RSV, according to the Centers for Disease Control and Prevention. Moderna aims to differentiate its RSV shot from the competition by offering single-dose, pre-filled syringes, which it says will save time and cut the risk of errors in administering the vaccine. The approval comes after the FDA delayed its decision on the shot, originally expected by May 12 due to administrative constraints.
Factuality Level: 8
Factuality Justification: The article provides accurate and objective information about Moderna’s RSV vaccine receiving U.S. regulatory approval, its advantages over competitors, and the current situation of COVID-19 vaccine sales. It also mentions the competition with GSK and Pfizer’s vaccines and their respective performances in the market.
Noise Level: 3
Noise Justification: The article provides relevant information about Moderna’s RSV vaccine approval and its competition with other vaccines but lacks in-depth analysis or exploration of the broader implications. It also includes some irrelevant details about stock performance.
Public Companies: Moderna Inc. (MRNA), Pfizer Inc. (PFE), GSK PLC (GSK)
Key People:
Financial Relevance: Yes
Financial Markets Impacted: The approval of Moderna’s RSV vaccine impacts the financial markets and companies involved in the pharmaceutical industry, particularly Moderna, GSK, and Pfizer.
Financial Rating Justification: The article discusses the regulatory approval of a new vaccine by Moderna, which can impact sales for both Moderna and its competitors GSK and Pfizer. This can affect their stock prices and market performance.
Presence Of Extreme Event: No
Nature Of Extreme Event: Other
Impact Rating Of The Extreme Event: No
Extreme Rating Justification: There is no extreme event mentioned in the article. The content discusses the approval of Moderna’s respiratory syncytial virus (RSV) vaccine for older adults, which could potentially impact the market competition with other RSV vaccines and have an effect on the companies involved.
www.marketwatch.com 
